Listing 5.09 Liver Transplantation in 2026: The Automatic 12 Month SSDI Approval from Transplant Date, How the CDR Actually Works, When Rejection Episodes and HCV Recurrence and Immunosuppression Toxicity Extend the Disability Period, and How the SSA CLD Score Under 5.05G Can Establish an Earlier Onset Date

By Anthony Albert, Benefits Research Director. Published July 24, 2026.

If you had a liver transplant, SSA considers you disabled for 1 year from the transplantation date, automatic. No functional testing during the window. No proof of rejection required. Just the transplant date and the fact that it happened.

The 1 year rule under Listing 5.09 is short compared to some other transplants. A lung transplant gets 3 years under Listing 3.11. A bone marrow or stem cell transplant gets 12 months from infusion under Listing 7.17. A liver transplant gets 12 months and then you face a Continuing Disability Review (CDR).

Most liver transplant patients meet a disability listing before the surgery. End-stage liver disease with variceal bleeding, refractory ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, or hepatic encephalopathy typically meets Listing 5.05 (Chronic Liver Disease) in the months and sometimes years leading up to transplant. That matters because it can establish an earlier disability onset date and open the door to retroactive benefits.

This article covers the exact 5.09 text, how the 1 year window works, what happens at the CDR, common complications that extend disability under 5.05 or other listings, indications for liver transplant that trigger a claim, pediatric 105.09, and how the SSA CLD score can anchor an onset date months before transplant. Four worked cases at the end.

The Listing 5.09 Text

Section 5.00G explains the rule further. If you receive a liver transplant, small intestine transplant, or pancreas transplant, you are considered disabled under the listing for 1 year from the transplant date. After that, SSA evaluates residual impairment based on:

• Adequacy of post-transplant liver function
• Requirement for post-transplant antiviral therapy
• Frequency and severity of rejection episodes
• Comorbid complications
• All adverse treatment effects

SSA notes explicitly that most liver transplant patients meet the definition of disability well before the transplant occurs. The 12 month clock does not restrict the disability onset date. Onset can be established months or years earlier based on the underlying liver disease.

What "Consider Under a Disability for 1 Year" Means

The 12 month window is an automatic Step 3 approval. SSA does not test your functional capacity during this period. You do not need to submit ADL forms, symptom evaluations, or medical opinions. The transplant date and the fact of transplantation are sufficient.

You should still submit records that document the underlying disease, the pre-transplant course, the transplant admission, and any early complications. This matters for two reasons:

1. It establishes an earlier disability onset date, which drives retroactive benefits
2. It positions the file for the CDR that comes at 12 to 15 months, when SSA will look for residual impairment

Indications for Liver Transplant That Route Through 5.09

Section 5.00G lists five categories of indications for liver transplantation:

Metabolic liver disease

Inherited or acquired metabolic disorders that progress to liver failure. Includes hereditary hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency (adult onset), cystic fibrosis with liver involvement, glycogen storage diseases, urea cycle disorders, familial amyloidosis (TTR), and non-alcoholic steatohepatitis (NASH, now called MASH: metabolic dysfunction-associated steatohepatitis).

Progressive liver failure

Chronic liver disease that has advanced through cirrhosis to decompensation. Common causes include chronic hepatitis B, chronic hepatitis C (though HCV cure with direct-acting antivirals has reduced the transplant list impact), alcohol-associated liver disease, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, MASH cirrhosis, and cryptogenic cirrhosis.

Life-threatening complications of liver disease

Complications that indicate imminent decompensation risk even without frank cirrhosis. Includes refractory variceal bleeding, refractory ascites, hepatorenal syndrome, hepatopulmonary syndrome, hepatic encephalopathy, and portopulmonary hypertension.

Hepatic malignancy

Hepatocellular carcinoma (HCC) within Milan criteria (single tumor 5 cm or smaller, or up to 3 tumors each 3 cm or smaller, without vascular invasion or extrahepatic spread) or UCSF criteria (expanded). Cholangiocarcinoma (intrahepatic and hilar in select centers), hepatoblastoma in pediatric cases, and select metastatic disease (neuroendocrine tumors).

Acute fulminant hepatitis

Acute liver failure from viral hepatitis (HAV, HBV, HEV), drug-induced liver injury (acetaminophen overdose most common), toxin-induced liver injury (Amanita phalloides mushroom, industrial hepatotoxins), autoimmune, Wilson disease presenting acutely, or unknown cause. Median time from symptom onset to encephalopathy under 26 weeks. Requires urgent transplant listing (Status 1A allocation, highest priority).

MELD, MELD-Na, and MELD 3.0: How Livers Are Allocated

Liver allocation in the US is based on the MELD-Na score (Model for End-Stage Liver Disease with sodium correction), transitioning to MELD 3.0 which incorporates female sex and albumin. Score range is 6 to 40. Higher score means higher priority. General allocation thresholds:

• MELD 15 and above: benefit from transplant exceeds mortality risk of surgery
• MELD 20 to 25: transplant listing standard
• MELD 30 and above: high urgency
• MELD 40: theoretical maximum, extreme urgency
• Status 1A: acute liver failure, expected survival under 7 days without transplant

MELD exception points apply for HCC within Milan criteria, hepatopulmonary syndrome, portopulmonary hypertension, cystic fibrosis, primary hyperoxaluria, familial amyloidosis, and pediatric metabolic diseases. These allow patients with lower calculated MELD but high mortality risk to receive priority.

Pre-Transplant Onset Under Listing 5.05 and the SSA CLD Score

Most liver transplant patients meet Listing 5.05 (Chronic Liver Disease) in the months before transplant. 5.05 has seven paragraphs (A through G), and any one paragraph independently qualifies:

• 5.05A variceal bleeding requiring transfusion of at least 2 units within a 12 month period
• 5.05B ascites or hydrothorax present on two evaluations 60 days apart within a 6 month period, with albumin 3.0 g/dL or less or INR 1.5 or more
• 5.05C spontaneous bacterial peritonitis with peritoneal fluid neutrophil count 250 or more
• 5.05D hepatorenal syndrome with creatinine 2.0 mg/dL or more or urinary sodium 10 mEq/L or less or oliguria under 500 mL/24 hr
• 5.05E hepatopulmonary syndrome with room air ABG PaO2 below 60 (sea level), 55 (3000 to 6000 ft), or 50 (above 6000 ft)
• 5.05F hepatic encephalopathy with two documented episodes plus asterixis or abnormal EEG or albumin 3.0 or INR 1.5 within 6 months, or a TIPS shunt
• 5.05G two SSA CLD scores 60 days apart within a 12 month period, both meeting SSA CLD 22 or higher (score is like MELD-Na but rounded)

The SSA CLD score calculation

Under 5.05G, the SSA Chronic Liver Disease score uses this formula:

SSA CLD (initial) = 9.57 x log(creatinine mg/dL) + 3.78 x log(bilirubin mg/dL) + 11.2 x log(INR) + 6.43

Rounded to the nearest whole integer. If the initial value is 11 or below, that is the SSA CLD score. If the initial value is above 11, apply the sodium correction:

SSA CLD = SSA CLD(i) + 1.32 x (137 - serum sodium mmol/L) - [0.033 x SSA CLD(i) x (137 - serum sodium mmol/L)]

Two scores 60 days apart, both 22 or more, within a 12 month window, meet 5.05G. This is the equivalent of a MELD-Na of about 22.

The date of the first SSA CLD score is the earliest disability onset date SSA will accept under 5.05G. For a patient transplanted in July with SSA CLD scores from January (25) and March (28), disability onset is set at January, giving 6 months of retroactive benefits plus the automatic 12 months post-transplant.

What Happens at the 12 Month CDR

Under POMS DI 28010.030, Listing 5.09 is a "listing with a specified timeframe" and triggers CDR at the 12 to 15 month mark. SSA reviews residual impairment against these five factors from 5.00G:

1. Post-transplant liver function

Recent LFTs (ALT, AST, alkaline phosphatase, bilirubin, GGT, albumin, INR), synthetic function markers, and liver biopsy if performed. Persistent elevation in any marker suggests ongoing dysfunction. Direct evaluation under 5.05 possible if elevations meet 5.05B (albumin) or 5.05F (INR).

2. Post-transplant antiviral therapy

If HCV was the transplant indication, direct-acting antivirals (DAAs like sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) can eradicate HCV with 95 percent plus SVR12. Some post-transplant patients require prolonged therapy or retreatment. HBV recipients require lifelong nucleoside analog therapy (entecavir, tenofovir) plus hepatitis B immunoglobulin (HBIG). Ongoing antiviral requirement itself is not disabling but supports treatment-related complications.

3. Frequency and severity of rejection episodes

Acute cellular rejection occurs in 20 to 40 percent of liver transplant recipients in the first year. Diagnosed by liver biopsy with Banff schema grading (mild, moderate, severe). Treatment is high-dose corticosteroids, and refractory cases receive antithymocyte globulin (ATG) or alemtuzumab. Chronic rejection (ductopenic rejection) presents as progressive cholestasis after 6 to 12 months and often requires retransplantation. Multiple rejection episodes in the first year suggest higher risk of chronic dysfunction and support continued disability.

4. Comorbid complications

Biliary complications (strictures, leaks) affect 10 to 30 percent of recipients. Vascular complications (hepatic artery thrombosis, portal vein thrombosis, IVC stenosis) affect 5 to 10 percent. Infection risk is highest in the first 6 months (CMV, EBV, fungal, PJP). New-onset diabetes after transplant (NODAT) occurs in 20 to 30 percent. Post-transplant lymphoproliferative disorder (PTLD) occurs in 1 to 3 percent within 5 years. HCC recurrence in Milan-criteria patients is 10 to 15 percent at 5 years. HCV recurrence with fibrosis was common before DAAs and is now rare.

5. Adverse treatment effects

Calcineurin inhibitor nephrotoxicity from tacrolimus or cyclosporine is nearly universal at 5 years, with 20 to 30 percent developing CKD stage 3b or worse. Evaluate under Listing 6.03 (dialysis), 6.04 (kidney transplant), or 6.05 (CKD with lab thresholds or complications). Corticosteroid effects include osteoporosis with fractures (Listing 1.19 pathologic fractures), diabetes, and cataracts (2.00 visual disorders). mTOR inhibitor effects include hyperlipidemia and pneumonitis. Immunosuppression-related secondary malignancies (skin cancers, PTLD, other) may qualify under Listing 13.00.

Pediatric Listing 105.09

Pediatric liver transplant recipients qualify under Listing 105.09 with identical language: 1 year from transplant date, then residual impairment evaluation. Pediatric indications include biliary atresia (most common), congenital metabolic disorders (tyrosinemia, urea cycle defects, Wilson disease, glycogen storage), progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, hepatoblastoma, and acute liver failure. Section 105.05H also gives an automatic 1 year disability for chronic liver disease with extrahepatic biliary atresia from diagnosis, which is a common pediatric transplant precursor.

Documentation Checklist

1. Pre-transplant medical records including diagnosis, imaging (US, CT, MRI), liver biopsy if performed, and progression notes
2. Complete lab history: LFTs, INR, albumin, creatinine, sodium, bilirubin (for SSA CLD score calculation under 5.05G)
3. Transplant evaluation notes from the transplant team, including MELD/MELD-Na scores over time
4. Transplant listing date and UNOS status changes
5. Transplant operative note with the exact date of transplantation (anchors the 12 month clock)
6. Transplant discharge summary and immediate post-op complications
7. Post-transplant follow-up notes at 1 month, 3 months, 6 months, and 12 months
8. Rejection biopsies with Banff grading
9. Immunosuppression medication list (tacrolimus, mycophenolate, prednisone, or alternatives)
10. Antiviral therapy record if HBV or HCV
11. Complication documentation: biliary studies (MRCP, ERCP), vascular imaging (Doppler US, CTA), infection cultures with sensitivities, glucose/HbA1c for NODAT, DEXA for osteoporosis
12. Treating hepatologist narrative statement or RFC

Four Worked Cases

Case One, Elena, 48, Illinois

Elena has PBC (primary biliary cholangitis) diagnosed 12 years ago with progressive cirrhosis. Ascites requiring paracentesis every 3 to 4 weeks for the past 8 months. Hepatorenal syndrome type 2 with creatinine climbing from 1.4 to 2.4 over 6 months. MELD-Na 26, then 30 over the same 6 months. She received a deceased donor liver transplant on April 12, 2026. Pre-transplant, she had two SSA CLD scores of 24 and 28 obtained in October and December 2025. She filed for SSDI on January 15, 2026. Disability onset established at October 15, 2025 (first SSA CLD score date). Automatic disability through April 11, 2027. CDR scheduled at 15 months.

Case Two, Marcus, 55, Texas

Marcus has MASH cirrhosis with HCC diagnosed on surveillance MRI. Single 3.5 cm lesion within Milan criteria, no vascular invasion. He received a deceased donor liver transplant on August 20, 2025. Explant pathology showed the primary tumor plus a 1.2 cm satellite not seen on pre-transplant imaging. At 10 months post-transplant, surveillance MRI shows a 2.1 cm new lesion in segment 7 with rising AFP (128, then 340). HCC recurrence confirmed by biopsy. Evaluation moves to Listing 13.19 (liver cancer) at the CDR. Disability continues.

Case Three, Sofia, 3, Georgia

Sofia has biliary atresia diagnosed at 6 weeks of age. Failed Kasai hepatoportoenterostomy. Portal hypertension with variceal bleeding at age 18 months. Received deceased donor liver transplant at age 2. Approved under 105.05H (extrahepatic biliary atresia) from diagnosis, and under 105.09 for 12 months from transplant. Post-transplant course complicated by acute cellular rejection at day 45 (Banff grade II, treated with steroid pulse) and CMV enteritis at day 90. At 15 month CDR, growth remains below 5th percentile, LFTs mildly elevated, ongoing tacrolimus with renal function declining (eGFR 65). SSI benefits continue under Listing 5.00 residual evaluation plus growth failure documentation.

Case Four, David, 61, Michigan

David has alcohol-associated cirrhosis with 8 years of documented abstinence and mental health treatment. Decompensation with grade 3 hepatic encephalopathy and refractory ascites led to transplant listing. Received deceased donor liver transplant on November 5, 2024. Uncomplicated post-op course. At 12 month CDR (November 2025), LFTs normal, creatinine 1.1, no rejection episodes, tacrolimus and mycophenolate tolerated. He returns to part-time work at month 14 and reaches SGA at month 18. SSDI benefits terminate at month 20 under medical improvement per 20 CFR 404.1594. Trial work period rules apply on return-to-work timing.

Denial Counters

Denial reason: transplant was less than 12 months before filing

5.09 does not have a look-back rule. The 12 months runs from the transplant date. File as soon as the transplant is scheduled or as soon as possible after surgery. Disability onset can be established earlier based on pre-transplant liver disease meeting 5.05.

Denial reason: DDS wants proof of severity during the 12 month window

The 5.09 rule is unconditional. No severity proof needed during the 12 month window. Cite 5.00G explicitly and attach the transplant operative note. If DDS is asking for functional testing, escalate to the file supervisor or reconsideration.

Denial reason: onset date set at transplant date, not pre-transplant

Under 5.05G and 5.00A, disability onset can be established months or years before transplant if the pre-transplant course meets a listing. Submit two SSA CLD scores 60 days apart, both 22 or higher, from the pre-transplant period. Also submit variceal bleeding records under 5.05A, ascites documentation under 5.05B, SBP records under 5.05C, HRS records under 5.05D, HPS ABG under 5.05E, or hepatic encephalopathy records under 5.05F.

Denial reason: CDR terminated at 12 months despite ongoing complications

Appeal within 60 days. Elect to continue benefits during appeal (10 day rule). Submit updated records showing residual impairment: rejection biopsies, immunosuppression toxicity (calcineurin nephropathy), infection episodes, new comorbidities (NODAT, osteoporosis, CKD from CNI), and HCC recurrence if applicable. Argue continued qualification under 5.05 residual criteria or under the relevant body system listing.

State Considerations

Liver transplant volumes concentrate in centers with active liver programs. Highest volume adult centers include hospitals in California (UCSF, UCLA, Cedars-Sinai), Texas (Baylor Dallas, Methodist San Antonio, Houston Methodist), Pennsylvania (UPMC, Penn), New York (Mount Sinai, NYU, Weill Cornell), Florida (Mayo Jacksonville, Miami), and Ohio (Cleveland Clinic, Ohio State).

Pediatric liver transplant centers concentrate at Cincinnati Children's, Children's Hospital of Philadelphia, Boston Children's, Texas Children's, Ann Arbor Michigan Medicine, Seattle Children's, and Denver Colorado Children's.

Regional MELD variability matters for pre-transplant onset dates. UNOS Region 5 (California) historically has higher MELD at transplant (median around 30) than Region 3 (Southeast) or Region 11 (Southeast/mid-Atlantic). Higher pre-transplant MELD means longer pre-transplant disability period supported by SSA CLD scores.

Related Blue Book Reading

• Listing 5.05 Chronic Liver Disease
• Listing 3.11 Lung Transplantation
• Listing 4.09 Heart Transplant
• Listing 7.17 Bone Marrow or Stem Cell Transplantation
• Listings 6.03 / 6.04 / 6.05 Chronic Kidney Disease and Kidney Transplant

Frequently Asked Questions